Status:
COMPLETED
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
Brief Summary
The objective of this post-marketing surveillance study is to evaluate the incidence of adverse events in Japanese subjects with pulmonary arterial hypertension treated with ambrisentan basd on prescr...
Eligibility Criteria
Inclusion
- Must use ambrisentan for the first time
Exclusion
- Subjects with hypersensitivity to ambrisentan
- Subjects who is pregnant or might be pregnant
- Subjects with severe hepatic disorder
Key Trial Info
Start Date :
December 14 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2020
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT01406327
Start Date
December 14 2010
End Date
February 28 2020
Last Update
September 3 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.